In yesterday’s Wall Street session, Arcutis Biotherapeutics Inc. (NASDAQ:ARQT) shares traded at $8.38, down -6.79% from the previous session.
ARQT stock price is now -30.47% away from the 50-day moving average and -49.29% away from the 200-day moving average. The market capitalization of the company currently stands at $513.61M.
25-cent Stock Takes $11T Commodities Sector Digital
One brilliantly-run technology firm has successfully partnered with some of the largest players in the industry to bring a first-of-its-kind digital solution to the global commodities supply chain sector. Best of all, this upstart technology firm is currently trading undiscovered — below 25-cents per share — so very, very few investors know about it yet! For investors… it's an early-stage opportunity in a company that's bringing the US$11T global commodities sector straight into the 21st century.
All the details are in the FREE online report you can get here.
Sponsored
In other news, Welgus Howard G., Director sold 8,500 shares of the company’s stock on Apr 17. The stock was sold for $118,728 at an average price of $13.97. Upon completion of the transaction, the Director now directly owns 165,825 shares in the company, valued at $1.39 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Apr 06, Director Welgus Howard G. sold 8,500 shares of the business’s stock. A total of $102,085 was realized by selling the stock at an average price of $12.01. This leaves the insider owning 165,825 shares of the company worth $1.39 million. Insiders disposed of 727,155 shares of company stock worth roughly $6.09 million over the past 1 year. A total of 1.40% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in ARQT stock. A new stake in Arcutis Biotherapeutics Inc. shares was purchased by MARSHALL WACE, LLP during the first quarter worth $19,319,000. SUVRETTA CAPITAL MANAGEMENT, LLC invested $5,693,000 in shares of ARQT during the first quarter. In the first quarter, OPALEYE MANAGEMENT INC. acquired a new stake in Arcutis Biotherapeutics Inc. valued at approximately $4,207,000. SEI INVESTMENTS CO acquired a new stake in ARQT for approximately $2,293,000. CENTIVA CAPITAL, LP purchased a new stake in ARQT valued at around $1,676,000 in the second quarter. In total, there are 219 active investors with 98.40% ownership of the company’s stock.
Thursday morning saw Arcutis Biotherapeutics Inc. (NASDAQ: ARQT) opened at $8.50. During the past 12 months, Arcutis Biotherapeutics Inc. has had a low of $8.87 and a high of $27.40. As of last week, the company has a debt-to-equity ratio of 1.42, a current ratio of 9.90, and a quick ratio of 9.70. The fifty day moving average price for ARQT is $12.00 and a two-hundred day moving average price translates $16.44 for the stock.
The latest earnings results from Arcutis Biotherapeutics Inc. (NASDAQ: ARQT) was released for Mar, 2023. According to the Biotechnology Company, earnings per share came in at -$1.31, missing analysts’ expectations of -$1.28 by -0.03. This compares to -$1.27 EPS in the same period last year. For the current quarter, analysts expect ARQT to generate $5.31M in revenue.
Arcutis Biotherapeutics Inc.(ARQT) Company Profile
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam formulation of roflumilast for the treatment of seborrheic dermatitis and scalp psoriasis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical formulation of ivarmacitinib designed to reach deeper into the skin in order to treat alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.
